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he Cardiorenal Syndrome
o We Need a Change
f Strategy or a Change of Tactics?*
ariell Jessup, MD, FACC,†
aria Rosa Costanzo, MD, FACC‡
hiladelphia, Pennsylvania; and Lombard, Illinois
wo disparate analyses appear in this issue of the Journal:
ne evaluates hemodynamics associated with worsening
enal function (WRF) in 145 patients hospitalized for
cutely decompensated heart failure (ADHF) (1), and the
ther assesses the correlation between hemodynamics, renal
unction, and mortality in 2,557 patients undergoing right
eart catheterization for various cardiovascular disorders (2).
espite the dissimilar patient populations, a strikingly
imilar message emerges: increased central venous pressure
CVP) is independently associated with renal dysfunction,
RF, and unfavorable outcomes. In the Dutch study, the
etrimental effect of CVP on renal function and survival was
reatest in those patients with preserved cardiac index (CI) (2).
See pages 582 and 589
The discordance between cardiac performance and renal
unction challenges the notion that, in heart failure (HF),
enal insufficiency usually represents hypoperfusion of the
idney as the result of poor forward flow or overzealous
iuresis (3). Instead, growing evidence shows that hyper-
olemia by itself is independently associated with mortality
4,5). The authors of a study comparing blood volume
easured by radiolabeled albumin with hemodynamics and
utcomes in 43 nonedematous patients with HF demon-
trated that 65% were hypervolemic (6). Importantly, blood
olume was closely correlated with pulmonary capillary wedge
ressure (PCWP) and independently predicted 1-year risk of
eath or urgent cardiac transplantation, both significantly
reater in the hypervolemic patients (6). Observational data
n patients with ADHF showed that pre-discharge reduc-
ion of PCWP16 mm Hg, as opposed to an increased CI,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Cardiovascular Division, Department of Medicine, University of
ennsylvania School of Medicine, Philadelphia, Pennsylvania; and the ‡Midwest
eart Foundation, Lombard, Illinois. Dr. Costanzo is a consultant and has receivedp
peakers’ honoria from CHF Solutions. The Midwest Heart Foundation has received
research grant from CHF Solutions as a site for the Unload trial.redicted improved 2-year survival (7). Interestingly, in the
utch study, increased CVP on admission, as well as
nsufficient reduction of CVP during hospitalization, were
he strongest determinants for the development of WRF
1). In contrast, impaired CI on admission and improve-
ent in CI after intensive medical therapy had little effect
n WRF. These intriguing observations raise questions
bout our current management strategy for acute HF, which
as been to lower cardiac filling pressures while maintaining
r enhancing CI (8). What are the mechanisms by which
enous congestion worsens renal function, and why is
igorous diuresis alone so often ineffective?
Normally, 85% of the total plasma volume resides in the
enous circulation; only 15% is maintained in the arterial
ircuit. The primary regulation of renal sodium and water
xcretion and, thus, body fluid homeostasis, is modulated by
he smaller arterial circulation, enabling the system respon-
ible for the perfusion of the body’s vital organs to respond
o small changes in body fluid volume (9). Heart failure
esults in a decrease in CI and a decrease in intra-arterial
lood volume. Arterial hypovolemia inactivates the high-
ressure baroreceptors in the aortic arch and coronary sinus,
ttenuates the tonic inhibition of afferent parasympathetic
ignals to the central nervous system, and enhances sympa-
hetic efferent tone, with subsequent activation of the
enin-angiotensin-aldosterone system (RAAS) and non-
smotic release of arginine-vasopressin (AVP) (9). In the
idney, increased angiotensin II (Ang II) causes renal
fferent arteriolar vasoconstriction, resulting in decreased
enal blood flow (RBF) and increased filtration fraction.
ogether with renal nerve stimulation, the increased peri-
ubular capillary oncotic pressure and reduced peritubular
apillary hydrostatic pressure augment sodium reabsorption
n the proximal tubule. Angiotensin II also directly stimu-
ates proximal sodium reabsorption by activating sodium-
icarbonate cotransporters and apical sodium-hydrogen ex-
hangers (10). Finally, Ang II promotes aldosterone secretion,
hich boosts sodium reabsorption in the distal nephron (9).
mportantly, increased proximal sodium reabsorption decreases
istal sodium and water delivery, stimulating macula densa
ells to increase synthesis of renin that further amplifies
eurohormonal activation (11). Enhanced renal sodium and
ater reabsorption predominantly fills the compliant venous
irculation, increasing CVP and atrial pressures.
Normally, an increase in atrial pressure suppresses AVP
elease and enhances water diuresis, decreases renal sympa-
hetic tone, and augments natriuretic peptide secretion. In
atients with HF, these atrial–renal reflexes are over-
helmed by neurohormonal activation, evidenced by per-
istent renal sodium and water retention despite elevated
trial pressures (9). Transmission of venous congestion to
he renal veins further impairs the glomerular filtration rate
GFR) (Fig. 1). The authors of an isolated mammalian
idney study from 1931 showed that increased renal venous
ressure was associated with reduced RBF, urine flow, and
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The Cardiorenal Syndrome February 17, 2009:597–9rinary sodium chloride excretion, abnormalities that were
eversed by lowering renal venous pressure (12). Years later,
ypervolemia experimentally induced in dogs directly de-
reased GFR, independent of CI and RBF (13). A contem-
orary study in patients with ADHF revealed that an
ncreased intra-abdominal pressure from ascites and visceral
dema was correlated with the severity of renal dysfunction
nd that reduction of intra-abdominal pressure improved
enal function (14). Furthermore, in the ESCAPE (Evalu-
tion Study of Congestive Heart Failure and Pulmonary
rtery Catheterization Effectiveness) trial, right atrial pres-
ure emerged as the only hemodynamic variable correlated
ith baseline renal function, an independent predictor of
ortality and HF hospitalization (15).
Despite these provocative data, it is premature to con-
lude that therapies specifically aimed at the reduction of
VP will actually reduce renal dysfunction or mortality in
atients with HF. In the ESCAPE trial, therapy directed
oward lowering measured PCWP and CVP produced no
etter outcomes than management aimed to reduce exam-
ased CVP (15). Also unknown are the specific CVP values
hat must be achieved to improve renal function and
utcomes. Perhaps the strategy to reduce filling pressures in
F remains appropriate, but our heavy reliance on the tactic
f diuretics to achieve this goal may critically impact renal
unction and outcome. Loop diuretics act in the thick,
scending limb of the loop of Henle, near the macula densa.
oop diuretics block sodium chloride uptake in the macula
ensa, independent of any effect on sodium and water
alance, thereby stimulating the RAAS (16). This patho-
hysiology, and the growing literature documenting the
Figure 1 Impact of Venous Congestion on Glomerular Net Filtra
An illustration of the afferent and efferent pressures at a glomerular capillary in a
sure and venous congestion. PBC  hydrostatic pressure in Bowman’s capsule; PG
capillaries.dverse consequences of diuretic use on ADHF outcomes t17), has lead to exploration of other approaches. If fluid
emoval by an alternative therapy, such as ultrafiltration,
oes not exceed the interstitial fluid mobilization rate of 14
o 15 ml/min, further activation of the RAAS is avoided.
oreover, for the same fluid volume, more sodium is
emoved by isotonic ultrafiltration than by diuretic-induced
ypotonic diuresis (18). Data from the UNLOAD (Ultra-
ltration vs IV Diuretics for Patients Hospitalized for Acute
ecompensated Congestive Heart Failure) trial on ADHF
ehospitalization rates after ultrafiltration appear promising
nd await further confirmation in larger trials (19).
Acute HF decompensation identifies patients at an in-
reased risk for rehospitalization and death (20). Poor out-
omes after a single ADHF episode suggests that ADHF
ccelerates disease progression. Hypervolemia may be associ-
ted with myocardial edema which, together with RAAS
ctivation, inflammatory cytokines, nitric oxide dysregula-
ion, oxidative and mechanical stress, and inotrope-induced
ncrease in myocardial oxygen consumption, create the
perfect storm,” leading to myocyte injury or death. The
athologic events complicating ADHF also may cause acute
enal injury by further reducing renal perfusion, oxygen
elivery, GFR, and responsiveness to natriuretic peptides.
n fact, renal dysfunction is the strongest predictor of poor
utcomes in patients with HF, regardless of whether systolic
unction is decreased or preserved.
The cardiorenal syndrome recently has been classified
ccording to whether the impairment of each organ is
rimary, secondary, or whether heart and kidney dysfunc-
ion occurs simultaneously as a result of a systemic disease,
s outlined in Table 1 (21). A consensus definition of each
Pressure
t with normal hemodynamics and a patient with increased right atrial (RA) pres-
lomerular capillary hydrostatic pressure; GC  oncotic pressure in glomerulartion
patien
C  gype of cardiorenal syndrome may help to design random-
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February 17, 2009:597–9 The Cardiorenal Syndromezed controlled trials aimed at identifying pathophysiologi-
ally sound interventions targeting specific patient popula-
ions. At the outset, the precise relationships between CVP
nd renal function should be prospectively evaluated and
onfirmed. The next logical step will be to test the strategy
hat therapies specifically aimed at reducing CVP will
avorably affect renal function, attenuate HF progression,
nd improve outcomes. Finally, the specific effects of dif-
erent interventions, or tactics, should be tested in prospec-
ive randomized trials.
eprint requests and correspondence: Dr. Mariell Jessup, Heart
ailure/Transplant Program, University of Pennsylvania Health
ystem, 6 Penn Tower, 3400 Spruce Street, Philadelphia, Penn-
ylvania 19104. E-mail: Mariell.Jessup@uphs.upenn.edu.
EFERENCES
1. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous
congestion for worsening of renal function in advanced decompensated
heart failure. J Am Coll Cardiol 2009;53:589–96.
2. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen
DJ, Hillege HL. Increased central venous pressure is associated with
impaired renal function and mortality in a broad spectrum of patients
ardiorenal Syndrome
Table 1 Cardiorenal Syndrome
Type I: acute cardiorenal syndrome
Abrupt worsening of cardiac function (e.g., acute cardiogenic shock or acutely
decompensated heart failure) leading to acute kidney injury.
Type II: chronic cardiorenal syndrome
Chronic abnormalities in cardiac function (e.g., chronic heart failure) causing
progressive and potentially permanent chronic kidney disease.
Type III: acute renocardiac syndrome
Abrupt worsening of renal function (e.g., acute kidney ischemia or
glomerulonephritis) causing acute cardiac disorder (e.g., heart failure,
arrhythmia, ischemia).
Type IV: chronic renocardiac syndrome
Chronic kidney disease (e.g., chronic glomerular or interstitial disease)
contributing to decreased cardiac function, cardiac hypertrophy, and/or
increased risk of adverse cardiovascular events.
Type V: secondary cardiorenal syndrome
Systemic condition (e.g., diabetes mellitus, sepsis) causing both cardiac and
renal dysfunction.
dapted, with permission, from Ronco et al. (21).with cardiovascular disease. J Am Coll Cardiol 2009;53:582–8. p3. Guyton AC, Jones CE. Central venous pressure: physiological signif-
icance and clinical implications. Am Heart J 1973;86:431–7.
4. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic
importance of elevated jugular venous pressure and a third heart sound
in patients with heart failure. N Engl J Med 2001;345:574–81.
5. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of
tolvaptan, a vasopressin antagonist, in patients hospitalized with
worsening heart failure: a randomized controlled trial. JAMA 2004;
291:1963–71.
6. Androne AS, Hryniewicz K, Hudaihed A, Mancini D, Lamanca J,
Katz SD. Relation of unrecognized hypervolemia in chronic heart
failure to clinical status, hemodynamics, and patient outcomes. Am J
Cardiol 2004;93:1254–9.
7. Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained
hemodynamic efficacy of therapy tailored to reduce filling pressures in
survivors with advanced heart failure. Circulation 1997;96:1165–72.
8. Heart Failure Society of America. HFSA 2006 comprehensive heart
failure practice guideline. J Card Fail 2006;12:e1–2.
9. Schrier RW. Role of diminished renal function in cardiovascular
mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006;
47:1–8.
0. Schrier RW. Body fluid volume regulation in health and disease: a
unifying hypothesis. Ann Intern Med 1990;113:155–9.
1. Castrop H, Schweda F, Mizel D, et al. Permissive role of nitric oxide
in macula densa control of renin secretion. Am J Physiol 2004;286:
F848–57.
2. Winton F. The influence of venous pressure on the isolated mamma-
lian kidney. J Physiol 1931;72:49–61.
3. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct
cause of renal sodium retention in oedema? Lancet 1988;1:1033–5.
4. Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal
pressure in acute decompensated heart failure: a potential contributor
to worsening renal function? J Am Coll Cardiol 2008;51:300–6.
5. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions:
insights from the ESCAPE trial. J Am Coll Cardiol 2008;51:1268–74.
6. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate
antidiuresis. N Engl J Med 2007;356:2064–72.
7. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between
dose of loop diuretics and outcomes in a heart failure population:
results of the ESCAPE trial. Eur J Heart Failure 2007;9:1064–9.
8. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in
functional capacity after removal of body fluid with isolated ultrafil-
tration in chronic cardiac insufficiency: failure of furosemide to provide
the same result. Am J Med 1994;96:191–9.
9. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus
intravenous diuretics for patients hospitalized for acute decompensated
heart failure. J Am Coll Cardiol 2007;49:675–83.
0. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and
determinants of survival in patients newly hospitalized for heart failure:
a population-based study. Arch Intern Med 2002;162:1689–94.
1. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardio-
renal syndrome. J Am Coll Cardiol 2008;52:1527–39.
ey Words: renal function y central venous pressure y mortality y
rognosis y heart catheterization.
